Acurx Pharmaceuticals (NASDAQ:ACXP) Releases Earnings Results, Beats Estimates By $0.07 EPS

Acurx Pharmaceuticals (NASDAQ:ACXPGet Rating) issued its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07, MarketWatch Earnings reports.

Shares of NASDAQ:ACXP traded down $0.69 on Thursday, reaching $2.61. The company had a trading volume of 75,330 shares, compared to its average volume of 24,690. Acurx Pharmaceuticals has a twelve month low of $2.61 and a twelve month high of $8.74. The stock has a 50-day moving average price of $3.69 and a 200 day moving average price of $4.18.

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. BlackRock Inc. raised its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXPGet Rating) by 149.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,699 shares of the company’s stock after acquiring an additional 10,014 shares during the period. BlackRock Inc. owned about 0.16% of Acurx Pharmaceuticals worth $55,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.72% of the company’s stock.

Acurx Pharmaceuticals Company Profile (Get Rating)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.

Read More

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with's FREE daily email newsletter.